24/7 Market News Snapshot 24 October, 2024 – Vaccinex, Inc. Common Stock (NASDAQ:VCNX)

October 24, 2024

DENVER, Colo., 24 October, 2024 (247marketnews.com) – (NASDAQ:VCNX) are discussed in this article.
Vaccinex, Inc. has seen a surge in its stock value, opening at $2.78 and currently trading at $3.27, which represents an impressive increase of approximately 19.78%. This rise follows a previous session close of $2.73 and is accompanied by a robust trading volume of 518.20K shares, indicating heightened investor confidence and substantial market interest. The technical indicators suggest that this breakout could pave the way for continued upward momentum, warranting close monitoring of potential resistance levels.

In a significant development for the company, Vaccinex is set to present groundbreaking data from its SIGNAL-AD clinical study at the forthcoming Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid on October 31, 2024. This presentation will highlight the efficacy and safety results of pepinemab, an innovative anti-SEMA4D antibody specifically designed for Alzheimer’s disease. Dr. Elizabeth Evans, Chief Operating Officer and Senior Vice President of Discovery and Translational Medicine at Vaccinex, will lead the session focusing on the randomized, double-blind phase 1b/2 SIGNAL-AD trial involving patients with Mild Cognitive Impairment and Mild Dementia linked to Alzheimer’s.

The anticipated outcomes from this trial are pivotal, as they aim to unveil the impact of pepinemab on cognitive decline, alongside its effect on crucial biomarkers of disease progression, including glial fibrillary acidic protein and phosphorylated tau peptide. Insights from this study are expected to contribute significantly to the understanding of neurotoxic mechanisms in Alzheimer’s disease and explore new treatment avenues, potentially redefining therapeutic strategies.

As details emerge from the SIGNAL-AD clinical study, Vaccinex remains at the forefront of Alzheimer’s research, with its findings poised to offer a pathway for more effective interventions in this complex neurodegenerative disorder. The company’s commitment to advancing treatment options underscores its role in addressing the substantial challenges posed by Alzheimer’s disease, aiming to improve patient outcomes and quality of life.

Related news for (VCNX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.